Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nivolumab combination therapy as first-line treatments for unresectable, advanced or metastatic esophageal squamous cell carcinoma

Published:2023-05-08 Issue:6 Volume:23 Page:565-571
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Rogers Jane E.¹,Yamashita Kohei²,Sewastjanow-Silva Matheus²^ORCID,Rosa Vicentini Ernesto²,Waters Rebecca³,Ajani Jaffer A.²

Affiliation:

1. Departments of Pharmacy Clinical Programs, University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. Gastrointestinal Medical Oncology1, University of Texas MD Anderson Cancer Center, Houston, TX, USA

3. Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Funder

This paper received no funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2023.2207826

Reference51 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Esophageal Carcinoma

3. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

4. Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102

5. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2024-10

2. Efficacy and safety evaluation of first-line systemic treatments for unresectable esophageal squamous cell carcinoma: a network meta-analysis;Frontiers in Oncology;2024-09-09

3. Recent developments in immunotherapy for gastrointestinal tract cancers;Journal of Hematology & Oncology;2024-08-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3